Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells

References

• Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today. 2017;53(11):597–608. doi:10.1358/dot.2017.53.11.2725754
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Roschewski M, Longo DL, Wilson WH. CAR T-cell therapy for large B-cell lymphoma — who, when, and how? N Engl J Med. 2021;386(7):692–696. doi:10.1056/NEJMe2118899
   PubMed Web of Science ®Google Scholar
• Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84. doi:10.1038/s41408-021-00469-5
   PubMed Web of Science ®Google Scholar
• Rendo MJ, Joseph JJ, Phan LM, DeStefano CB. car t-cell therapy for patients with multiple myeloma: current evidence and challenges. Blood Lymphat Cancer. 2022;12:119–136. doi:10.2147/BLCTT.S327016
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Krönke G, Völkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567–569. doi:10.1056/NEJMc2107725
   PubMed Web of Science ®Google Scholar
• Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446–453. doi:10.1126/science.aay5967
   PubMed Web of Science ®Google Scholar
• Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N. Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther. 2020;27(10):799–809. doi:10.1038/s41417-019-0157-z
   PubMed Web of Science ®Google Scholar
• Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discov. 2018;17(3):161–162. doi:10.1038/nrd.2017.266
   PubMed Web of Science ®Google Scholar
• INCA MdS. Estimativa 2020 - Incidência de Câncer no Brasil. 2020.
   Google Scholar
• Tang J, Hubbard-Lucey VM, Pearce L, O’Donnell-Tormey J, Shalabi A. The global landscape of cancer cell therapy. Nat Rev Drug Discov. 2018;17(7):465–466. doi:10.1038/nrd.2018.74
   PubMed Web of Science ®Google Scholar
• Ghassemi S, Nunez-Cruz S, O’Connor RS, et al. Reducing ex vivo culture improves the antileukemic activity of Chimeric Antigen Receptor (CAR) T cells. Cancer Immunol Res. 2018;6(9):1100–1109. doi:10.1158/2326-6066.CIR-17-0405
   PubMed Web of Science ®Google Scholar
• Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther. 2009;17(5):767–777. doi:10.1038/mt.2009.41
   PubMed Web of Science ®Google Scholar
• Wagner DL, Fritsche E, Pulsipher MA, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:1–15.
   PubMed Web of Science ®Google Scholar
• J-Q M, Zhao W, Jing H, et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor–T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41(6):1275–1284.
   PubMed Web of Science ®Google Scholar
• Patel U, Abernathy J, Savani BN, Oluwole O, Sengsayadeth S, Dholaria B. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem. 2022;3:24–31. doi:10.1002/jha2.356
   PubMedGoogle Scholar
• Chicaybam L, Abdo L, Viegas M, et al. Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion. Gene Ther. 2020;27(1–2):85–95. doi:10.1038/s41434-020-0121-4
   PubMed Web of Science ®Google Scholar
• de Macedo Abdo L, Barros LRC, Saldanha Viegas M, et al. Development of CAR-T cell therapy for B-ALL using a point-of-care approach. Oncoimmunology. 2020;9(1):1752592. doi:10.1080/2162402X.2020.1752592
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. doi:10.1038/mto.2016.11
   PubMed Web of Science ®Google Scholar
• Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward. Front Immunol. 2020;11:702.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48. doi:10.1016/j.annonc.2020.10.478
   PubMed Web of Science ®Google Scholar
• Riedl SAB, Kaiser P, Raup A, Synatschke CV, Jérôme V, Freitag R. Non-viral transfection of human T lymphocytes. Processes. 2018;6(10):188. doi:10.3390/pr6100188
   Web of Science ®Google Scholar
• El-Mayta R, Zhang Z, Hamilton AG, Mitchell MJ. Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Ther. 2021;28(9):947–959. doi:10.1038/s41417-021-00336-2
   PubMed Web of Science ®Google Scholar
• Han X, Mitchell MJ, Nie G. Nanomaterials for therapeutic RNA delivery. Matter. 2020;3(6):1948–1975. doi:10.1016/j.matt.2020.09.020
   Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555. doi:10.1038/nrg3763
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Warzecha CC, Yadavali S, et al. Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device. Nano Lett. 2021;21(13):5671–5680. doi:10.1021/acs.nanolett.1c01353
   PubMed Web of Science ®Google Scholar
• Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36(9):777–778. doi:10.1038/nbt0918-777
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20(5):321–334. doi:10.1038/s41577-019-0269-6
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–289. doi:10.1038/s41586-021-03275-y
   PubMed Web of Science ®Google Scholar
• Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int J Nanomedicine. 2007;2(3):353–360.
   PubMed Web of Science ®Google Scholar
• Scalzo S, Santos AK, Ferreira HA, et al. Ionizable lipid nanoparticle-mediated delivery of plasmid DNA in cardiomyocytes. Int J Nanomedicine. 2022;17:2865–2881. doi:10.2147/IJN.S366962
   PubMed Web of Science ®Google Scholar
• Guimaraes PPG, Zhang R, Spektor R, et al. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. J Control Release. 2019;316:404–417. doi:10.1016/j.jconrel.2019.10.028
   PubMed Web of Science ®Google Scholar
• Billingsley MM, Hamilton AG, Mai D, et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 2022;22(1):533–542. doi:10.1021/acs.nanolett.1c02503
   PubMed Web of Science ®Google Scholar
• Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20(3):1578–1589. doi:10.1021/acs.nanolett.9b04246
   PubMed Web of Science ®Google Scholar
• Chen D, Love KT, Chen Y, et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012;134(16):6948–6951. doi:10.1021/ja301621z
   PubMed Web of Science ®Google Scholar
• Au - El-Mayta R, Au - Padilla MS, Au - Billingsley MM, Au - Han X, Au - Mitchell MJ. Testing the in vitro and in vivo efficiency of mRNA-lipid nanoparticles formulated by microfluidic mixing. JoVE. 2023;20(191):e64810.
   Google Scholar
• Bloemberg D, Nguyen T, MacLean S, et al. A high-throughput method for characterizing novel chimeric antigen receptors in Jurkat cells. Mol Ther Methods Clin Dev. 2020;16:238–254. doi:10.1016/j.omtm.2020.01.012
   PubMed Web of Science ®Google Scholar
• McComb S, Nguyen T, Shepherd A, et al. Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through hinge domain truncation. Front Immunol. 2022;2022:13.
   Google Scholar
• ANVISA. 2022. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/anvisa-aprova-produto-de-terapia-avancada-para-tratamento-de-cancer. Accessed July 23, 2022.
   Google Scholar
• Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM. CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol. 2018;9:1740. doi:10.3389/fimmu.2018.01740
   PubMed Web of Science ®Google Scholar
• Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:1–12.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fang Y, Chen X, et al. Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43):eaax7969. doi:10.1126/sciimmunol.aax7969
   PubMed Web of Science ®Google Scholar
• Zheng PP, Kros JM, Wang G. Elusive neurotoxicity in T cell-boosting anticancer therapies. Trends Immunol. 2019;40(4):274–278. doi:10.1016/j.it.2019.02.005
   PubMed Web of Science ®Google Scholar
• Guerrini G, Magrì D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol. 2022;17(6):570–576. doi:10.1038/s41565-022-01129-w
   PubMed Web of Science ®Google Scholar
• Zhao N, Qi J, Zeng Z, et al. Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex. J Control Release. 2012;159(1):104–110. doi:10.1016/j.jconrel.2012.01.007
   PubMed Web of Science ®Google Scholar
• LoPresti ST, Arral ML, Chaudhary N, Whitehead KA. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release. 2022;345:819–831. doi:10.1016/j.jconrel.2022.03.046
   PubMed Web of Science ®Google Scholar
• Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. P Natl Acad Sci USA. 2021;118(52). doi:10.1073/pnas.2109256118
   PubMedGoogle Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–1335. doi:10.1021/acs.nanolett.6b03329
   PubMed Web of Science ®Google Scholar
• Inoue T, Swain A, Nakanishi Y, Sugiyama D. Multicolor analysis of cell surface marker of human leukemia cell lines using flow cytometry. Anticancer Res. 2014;34(8):4539–4550.
   PubMed Web of Science ®Google Scholar
• Jiang J, Ahuja S. Addressing patient to patient variability for autologous CAR T therapies. J Pharm Sci. 2021;110(5):1871–1876. doi:10.1016/j.xphs.2020.12.015
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Chen GM, Wang M, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602(7897):503–509. doi:10.1038/s41586-021-04390-6
   PubMed Web of Science ®Google Scholar
• Bove C, Arcangeli S, Falcone L, et al. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J Immunother Cancer. 2023;11(1):e005878. doi:10.1136/jitc-2022-005878
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138. doi:10.1172/JCI85309
   PubMed Web of Science ®Google Scholar
• Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-cell selection affects Chimeric Antigen Receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38(17):1938–1950. doi:10.1200/JCO.19.03279
   PubMed Web of Science ®Google Scholar